AOTI, Inc. (AOTI) AI Stock Analysis

• Market Cap: £37.76M
• Dividend Yield: N/A
• Average Volume (3M): 36.39K
• Price to Earnings (P/E): 171.8
• Beta (1Y): 0.32
• Revenue Growth: 29.20%
• EPS Growth: 78.32%
• Country: UK
• Employees: 85
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Specialties
• EPS (TTM): N/A
• Shares Outstanding: 106,359,160
• 10 Day Avg. Volume: 30,736
• 30 Day Avg. Volume: 36,392
• PEG Ratio: -0.28
• Price to Book (P/B): 8.47
• Price to Sales (P/S): 2.53
• P/FCF Ratio: -18.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.03
• Revenue Forecast (FY): £74.60M

• Rating: 54 Neutral
• Price Target: 43.00 p ▲(56.36% Upside)
• Action: Reiterated Date: 01/15/26
• Date: Action: Reiterated 01/15/26

The score is primarily constrained by ongoing losses and weak cash flow sustainability despite strong revenue growth and improved margins. Technicals are supportive but show signs of being stretched, and valuation is pressured by negative earnings with no dividend support.

Positive Factors

Revenue growth and gross margin expansion

Sustained top-line growth combined with a dramatic gross margin improvement implies stronger product-market fit and scalable unit economics. Over 2–6 months this supports reinvestment in R&D and sales, improving competitive positioning and long-term gross-profit resilience.

Negative Factors

Persistent unprofitability

Ongoing net losses erode retained capital and require external funding to sustain growth. Over months this limits the firm's ability to self-finance expansion, increases dilution or debt risk, and challenges the transition from margin improvements to consistent net profitability.

AOTI, Inc. Business Overview & Revenue Model

Company Description

AOTI, Inc. engages in the development and sale of medical solutions for chronic wounds. Its products include the Topical Wound Oxygen (TWO2) Therapy and the NEXA NPWT (negative pressure wound therapy) System. The company was founded by Michael Ste...

Read more

AOTI, Inc. engages in the development and sale of medical solutions for chronic wounds. Its products include the Topical Wound Oxygen (TWO2) Therapy and the NEXA NPWT (negative pressure wound therapy) System. The company was founded by Michael Ste...

How the Company Makes Money

AOTI generates revenue through multiple streams, including the sale of its proprietary optical systems and imaging software to healthcare providers, research institutions, and industrial clients. The company also engages in ongoing service contrac...

Read more

AOTI generates revenue through multiple streams, including the sale of its proprietary optical systems and imaging software to healthcare providers, research institutions, and industrial clients. The company also engages in ongoing service contrac...

AOTI, Inc. Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	30.16M	58.36M	43.92M	8.86M	889.10K
Gross Profit	15.80M	51.35M	37.59M	2.86M	45.36K
EBITDA	3.20M	2.64M	-4.28M	475.61K	3.58M
Net Income	560.66K	-1.76M	-8.19M	1.74M	-86.82K
Balance Sheet
Total Assets	54.38M	39.54M	21.08M	9.35M	1.51M
Cash, Cash Equivalents and Short-Term Investments	14.37M	9.34M	778.48K	2.56M	220.20K
Total Debt	21.30M	8.92M	12.35M	4.45M	805.51K
Total Liabilities	36.64M	22.10M	26.99M	5.94M	1.25M
Stockholders Equity	17.74M	17.44M	-5.91M	3.41M	258.29K
Cash Flow
Free Cash Flow	-5.44M	-7.85M	-2.76M	1.77M	-428.43K
Operating Cash Flow	-4.28M	-5.91M	-1.45M	2.77M	-46.07K
Investing Cash Flow	-1.13M	-1.94M	-1.59M	-1.23M	-392.10K
Financing Cash Flow	7.62M	16.41M	-202.81K	648.65K	490.97K

AOTI, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 27.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AOTI, the sentiment is Neutral. The current price of 27.5 is below the 20-day moving average (MA) of 33.40, below the 50-day MA of 36.98, and below the 200-day MA of 46.47, indicating a neutral trend. The MACD of -0.96 indicates Negative momentum. The RSI at 55.26 is Neutral, neither overbought nor oversold. The STOCH value of 77.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:AOTI.

AOTI, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EKF	66 Neutral	£100.85M	55.78	3.01%	―	-1.43%	28.57%
VRCI	58 Neutral	£7.19M	-0.39	-122.54%	―	-57.03%	-15.71%
DXRX	57 Neutral	£130.70M	-5.17	-3.95%	―	31.83%	46.59%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
AOTI	54 Neutral	£37.76M	171.81	3.19%	―	29.20%	78.32%
ABDX	45 Neutral	£20.09M	-2.69	-58.27%	―	37.39%	-126.19%
RENX	39 Underperform	£8.96M	―	425.97%	―	-4.48%	61.09%